Sera Prognostics, Inc.

SERA Healthcare Medical Devices

Sera Prognostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $81,000.00, up 5.19% from fiscal 2024.

Revenue
+162.5%
EPS
0.00%
Free cash flow
−12.8%

Quarter to September 2026, against a year earlier

2.09 0.01 +0.48%
Market cap
$82.1M
P/E
0.0×
Fwd P/E
−3.1×
Dividend yield
—
F-score
4/9
Altman Z
−2.09
Beneish M
n/a
Dividend safety
n/a

Sera Prognostics, Inc. (SERA) P/E ratio

Alert me on P/E ratio

Sera Prognostics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
21 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
LUCD Lucid Diagnostics Inc. compare n/m
ECOR electroCore, Inc. compare n/m
MBOT Microbot Medical Inc. compare n/m
SERA Sera Prognostics, Inc. n/m
NYXH Nyxoah SA compare n/m
OM Outset Medical, Inc. compare n/m
HYPR Hyperfine, Inc. compare n/m
ZOMDF Zomedica Corp. compare n/m
LNSR LENSAR, Inc. compare 3.9×
Medical Devices industry median 25.6×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on SERA